Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance
Pinpointing the genetic driver of a rare childhood leukemia subtype opens doors to tailored therapies for kids who resist standard chemotherapy.
The most comprehensive multi-omics characterization of pediatric AML-M0 to date identifies RUNX1 loss-of-function mutations as the primary biological and clinical determinant of this rare chemoresistant subtype, associated with global DNA hypomethylation reversal targets, RAS/FLT3/JAK pathway activation, and stem cell-like features. These findings directly inform precision therapy selection for a high-unmet-need pediatric population with historically poor outcomes.
What the study was
- Study design
- Multi-omics cohort analysis (23 pediatric AML-M0 vs 1483 leukemia controls); CRISPR functional validation
- Population
- Pediatric patients with AML-M0 (minimally differentiated AML); multi-institutional Japanese cohort
- Sample size
- 1506
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Leukemia
Why it surfaced
First large-scale multi-omics characterization of a rare, chemoresistant pediatric AML subtype (AML-M0); RUNX1 as actionable target with immediate precision therapy implications; published in Leukemia (high-impact hematology journal).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.